BACKGROUND: Our goal was to identify changes in the metabolome in multiple sclerosis (MS) and how vitamin D supplementation alters metabolic profiles in MS patients and healthy controls. METHODS: We applied global untargeted metabolomics to plasma from a cross-sectional cohort of age- and sex-matched MS patients and controls and a second longitudinal cohort of MS patients and healthy controls who received 5,000 IU cholecalciferol daily for 90 days. We applied partial least squares discriminant analysis, weighted correlation network analysis (WGCNA), and pathway analysis to the metabolomics data. Generalized estimating equations models were used to assess change in WGCNA-identified module scores or metabolite pathways with vitamin D supplementation. RESULTS: Utilizing multiple analytical techniques, we identified metabolic alterations in oxidative stress (γ-glutamyl amino acid, glutathione) and xenobiotic metabolism (benzoate, caffeine) in MS patients compared with healthy controls in the first cohort. In the vitamin D supplementation cohort, we identified two sets of metabolites altered differentially between MS patients and healthy controls with vitamin D supplementation. The first included markers of oxidative stress and protein oxidation (P = 0.006), while the second contained lysolipids and fatty acids (P = 0.03). CONCLUSIONS: Using metabolomics, we identified alterations in oxidative stress and xenobiotic metabolism in MS patients and subsequently demonstrated a reduction of oxidative stress markers with vitamin D supplementation in healthy controls but not in MS patients. We demonstrate the utility of metabolomics in identifying aberrant metabolic processes and in monitoring the ability of therapeutic interventions to correct these abnormalities. TRIAL REGISTRATION: ClinicalTrials.gov NCT01667796. FUNDING: This study was supported by NIH grant K23 NS067055, grants from the Race to Erase MS, the National Multiple Sclerosis Society, the American Academy of Neurology, and North American Research Committee on Multiple Sclerosis.
BACKGROUND: Our goal was to identify changes in the metabolome in multiple sclerosis (MS) and how vitamin D supplementation alters metabolic profiles in MSpatients and healthy controls. METHODS: We applied global untargeted metabolomics to plasma from a cross-sectional cohort of age- and sex-matched MSpatients and controls and a second longitudinal cohort of MSpatients and healthy controls who received 5,000 IU cholecalciferol daily for 90 days. We applied partial least squares discriminant analysis, weighted correlation network analysis (WGCNA), and pathway analysis to the metabolomics data. Generalized estimating equations models were used to assess change in WGCNA-identified module scores or metabolite pathways with vitamin D supplementation. RESULTS: Utilizing multiple analytical techniques, we identified metabolic alterations in oxidative stress (γ-glutamyl amino acid, glutathione) and xenobiotic metabolism (benzoate, caffeine) in MSpatients compared with healthy controls in the first cohort. In the vitamin D supplementation cohort, we identified two sets of metabolites altered differentially between MSpatients and healthy controls with vitamin D supplementation. The first included markers of oxidative stress and protein oxidation (P = 0.006), while the second contained lysolipids and fatty acids (P = 0.03). CONCLUSIONS: Using metabolomics, we identified alterations in oxidative stress and xenobiotic metabolism in MSpatients and subsequently demonstrated a reduction of oxidative stress markers with vitamin D supplementation in healthy controls but not in MSpatients. We demonstrate the utility of metabolomics in identifying aberrant metabolic processes and in monitoring the ability of therapeutic interventions to correct these abnormalities. TRIAL REGISTRATION: ClinicalTrials.gov NCT01667796. FUNDING: This study was supported by NIH grant K23 NS067055, grants from the Race to Erase MS, the National Multiple Sclerosis Society, the American Academy of Neurology, and North American Research Committee on Multiple Sclerosis.
Authors: Pavan Bhargava; Sonya U Steele; Emmanuelle Waubant; Nisha R Revirajan; Jacqueline Marcus; Marieme Dembele; Sandra D Cassard; Bruce W Hollis; Ciprian Crainiceanu; Ellen M Mowry Journal: Mult Scler Date: 2015-08-18 Impact factor: 6.312
Authors: Geng Zhang; Peijun He; Hanson Tan; Anuradha Budhu; Jochen Gaedcke; B Michael Ghadimi; Thomas Ried; Harris G Yfantis; Dong H Lee; Anirban Maitra; Nader Hanna; H Richard Alexander; S Perwez Hussain Journal: Clin Cancer Res Date: 2013-08-05 Impact factor: 12.531
Authors: Alex M Dickens; James R Larkin; Julian L Griffin; Ana Cavey; Lucy Matthews; Martin R Turner; Gordon K Wilcock; Benjamin G Davis; Timothy D W Claridge; Jacqueline Palace; Daniel C Anthony; Nicola R Sibson Journal: Neurology Date: 2014-09-24 Impact factor: 9.910
Authors: Marie Therese Fischer; Isabella Wimmer; Romana Höftberger; Susanna Gerlach; Lukas Haider; Tobias Zrzavy; Simon Hametner; Don Mahad; Christoph J Binder; Markus Krumbholz; Jan Bauer; Monika Bradl; Hans Lassmann Journal: Brain Date: 2013-05-17 Impact factor: 13.501
Authors: J Singh; M Cerghet; L M Poisson; I Datta; K Labuzek; H Suhail; R Rattan; Shailendra Giri Journal: J Neuroimmune Pharmacol Date: 2018-10-12 Impact factor: 4.147
Authors: Darius Häusler; Sebastian Torke; Evelyn Peelen; Thomas Bertsch; Marija Djukic; Roland Nau; Catherine Larochelle; Scott S Zamvil; Wolfgang Brück; Martin S Weber Journal: Brain Date: 2019-09-01 Impact factor: 13.501
Authors: S L Andersen; F B S Briggs; J H Winnike; Y Natanzon; S Maichle; K J Knagge; L K Newby; S G Gregory Journal: Mult Scler Relat Disord Date: 2019-03-09 Impact factor: 4.339
Authors: Enrique González-Madrid; Ma Andreina Rangel-Ramírez; María José Mendoza-León; Oscar Álvarez-Mardones; Pablo A González; Alexis M Kalergis; Ma Cecilia Opazo; Claudia A Riedel Journal: Int J Mol Sci Date: 2022-06-25 Impact factor: 6.208
Authors: Pavan Bhargava; Matthew D Smith; Leah Mische; Emily Harrington; Kathryn C Fitzgerald; Kyle Martin; Sol Kim; Arthur Anthony Reyes; Jaime Gonzalez-Cardona; Christina Volsko; Ajai Tripathi; Sonal Singh; Kesava Varanasi; Hannah-Noelle Lord; Keya Meyers; Michelle Taylor; Marjan Gharagozloo; Elias S Sotirchos; Bardia Nourbakhsh; Ranjan Dutta; Ellen M Mowry; Emmanuelle Waubant; Peter A Calabresi Journal: J Clin Invest Date: 2020-07-01 Impact factor: 14.808